{"id":432436,"title":"Notice Regarding Interim Approach for Evaluating Cardiovascular Risk for New Antidiabetic Therapies to Treat Type 2 Diabetes Mellitus - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-01-02","captureTimestamp":"2026-01-02T08:04:05.655000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/interim-approach-evaluating-cardiovascular-risk-new-antidiabetic-therapies-treat-type-2-diabetes-mellitus-notice.html","snippet":"Notice Regarding Interim Approach for Evaluating Cardiovascular Risk for New Antidiabetic Therapies to Treat Type 2 Diabetes Mellitus (PDF Version - 64 K) Contact: Bureau of Metabolism, Oncology and Reproductive Sciences (BMORS) Notice April 27, 2011 Our file number:…","rawSnapshotUrl":"/api/snapshots/raw/432436","browseUrl":"https://replay.healtharchive.ca/job-6/20260102080405/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/interim-approach-evaluating-cardiovascular-risk-new-antidiabetic-therapies-treat-type-2-diabetes-mellitus-notice.html#ha_snapshot=432436","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}